.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Doxorubicin hydrochloride - Generic Drug Details

« Back to Dashboard
Doxorubicin hydrochloride is the generic ingredient in five branded drugs marketed by Mylan Labs Ltd, Alvogen Inc, Janssen Res And Dev, Sun Pharm Inds, West-ward Pharms Int, Actavis Inc, Bristol Myers Squibb, Pharmacia And Upjohn, Pharmachemie Bv, Teva Pharms Usa, Sandoz Inc, Sun Pharma Global, Fresenius Kabi Usa, and Sagent Pharms, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for doxorubicin hydrochloride. Twelve suppliers are listed for this compound.

Summary for Generic Name: doxorubicin hydrochloride

Tradenames:5
Patents:0
Applicants:14
NDAs:20
Drug Master File Entries: see list16
Suppliers / Packaging: see list12
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: doxorubicin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DOXORUBICIN HYDROCHLORIDE
doxorubicin hydrochloride
INJECTABLE;INJECTION050629-003Mar 28, 2011RXNo► subscribe► subscribe
Sandoz Inc
DOXORUBICIN HYDROCHLORIDE
doxorubicin hydrochloride
INJECTABLE;INJECTION200146-001Jul 18, 2012RXNo► subscribe► subscribe
West-ward Pharms Int
DOXORUBICIN HYDROCHLORIDE
doxorubicin hydrochloride
INJECTABLE;INJECTION062921-003Mar 17, 1989RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: doxorubicin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Res And Dev
DOXIL (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION050718-001Nov 17, 19955,013,556► subscribe
Janssen Res And Dev
DOXIL (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION050718-002Jun 13, 20005,213,804► subscribe
Janssen Res And Dev
DOXIL (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION050718-002Jun 13, 20005,013,556► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc